ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-558-2871
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$223.81 million
Profitability
Miscellaneous
Employees430
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.05. The biopharmaceutical company had revenue of $59.57 million for the quarter, compared to analyst estimates of $59.46 million. ACADIA Pharmaceuticals had a negative return on equity of 77.14% and a negative net margin of 109.56%. The business's revenue was up 36.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.55) EPS. View ACADIA Pharmaceuticals' Earnings History.
When is ACADIA Pharmaceuticals' next earnings date?
What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?
ACADIA Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275-300 million, compared to the consensus revenue estimate of $297.15 million.
What price target have analysts set for ACAD?
10 equities research analysts have issued 12-month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $17.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $32.60 in the next year. This suggests a possible upside of 24.9% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.
What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.
What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. JPMorgan Chase & Co. analysts commented, "ACAD’s 4Q report this afternoon was relatively unsurprising. That said, we believe the company is making encouraging progress on both the commercial and clinical fronts ($60M in Nuplazid sales beat by $1-2M; 2019 Nuplazid guide above JPMe / in line with consensus; MDD pivotal program agreement reached; Phase 3 DRP/schizo studies on track). Indeed, the recovery for Nuplazid in PDP continues to build upon the early signals seen in 3Q18. Although we’re comfortable with Nuplazid’s commercial outlook, we expect 2019 to be less about PDP and more about the multiple important clinical readouts on tap that represent meaningfully larger future opportunities. In our view, a win on any of these clinical programs could lead to significant share appreciation." (3/3/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and our PT of $30 per share of ACAD. On Tuesday AMC, ACADIA reported 4Q18 revenues of $59.6M which were above our and approximately in line with consensus (FactSet) estimates. The company ended 4Q18 with a strong balance sheet consisting of $473.5M in cash. We model current cash and projected NUPLAZID revenues to fund ACADIA through several major value inflection points including topline data from the P3 ENHANCE study (schizo inadequate responders, mid-2019) and the P3 HARMONY study (DRP, 2020). YoY growth for NUPLAZID revenues was 79%." (2/27/2019)
- 3. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (1/31/2019)
- 4. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $69/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%)." (11/1/2018)
Has ACADIA Pharmaceuticals been receiving favorable news coverage?
News articles about ACAD stock have been trending somewhat positive on Saturday, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ACADIA Pharmaceuticals earned a coverage optimism score of 0.6 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY) and Perrigo (PRGO).
What other stocks do shareholders of ACADIA Pharmaceuticals own?
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen R. Davis, CEO & Director (Age 58)
- Dr. Srdjan R. Stankovic, Pres (Age 62)
- Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
- Ms. Elena Ridloff C.F.A., CFA, Interim CFO & Sr. VP of Investor Relations
- Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)
Who are ACADIA Pharmaceuticals' major shareholders?
ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (17.23%), BlackRock Inc. (8.10%), First Trust Advisors LP (3.31%), Great Point Partners LLC (2.20%), Northern Trust Corp (1.07%) and Geode Capital Management LLC (1.00%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Glenn Baity and Laura Brege. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Which major investors are selling ACADIA Pharmaceuticals stock?
ACAD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Hudson Bay Capital Management LP, Emory University, Peregrine Capital Management LLC, Jane Street Group LLC, Fosun International Ltd, Weiss Multi Strategy Advisers LLC and Wealthstreet Investment Advisors LLC. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Which major investors are buying ACADIA Pharmaceuticals stock?
ACAD stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Great Point Partners LLC, Norges Bank, Millennium Management LLC, PNC Financial Services Group Inc., BlackRock Inc., Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy shares of ACADIA Pharmaceuticals?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACAD stock can currently be purchased for approximately $26.10.
How big of a company is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a market capitalization of $3.76 billion and generates $223.81 million in revenue each year. The biopharmaceutical company earns $-245,190,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ACADIA Pharmaceuticals employs 430 workers across the globe.
What is ACADIA Pharmaceuticals' official website?
How can I contact ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
